Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Elbrønd, Bodil, Jakobsen, Grethe, Larsen, Søren, Agersø, Henrik, Jensen, Lisbeth Bjerring, Rolan, Paul, Sturis, Jeppe, Hatorp, Vibeke +1 more·2002·Diabetes Care
DOI 10.2337/diacare.25.8.1398

Cited by (284)

Items 101–200 of 284

  1. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria Jersild Jespersen, Filip Krag Knop, Mikkel Christensen · 2012 · Expert Opinion on Drug Metabolism & Toxicology
  2. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Luc F. Van Gaal, Stephen W. Gutkin, Michael Albrecht Nauck · 2008 · European Journal of Endocrinology
  3. Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
    Lotte Bjerre Knudsen · 2019 · ACS Pharmacology & Translational Science
  4. Incretin agents in type 2 diabetes.
    Stuart A. Ross, Jean-Marie Ékoé · 2010 · PubMed Central
  5. Population Pharmacokinetics of Liraglutide, a Once‐Daily Human Glucagon‐Like Peptide‐1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice‐Daily Exenatide
    Estelle Watson, Daniël Martijn Jonker, Lisbeth Vestergård Jacobsen, Steen H. Ingwersen · 2010 · The Journal of Clinical Pharmacology
  6. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Richard E. Pratley · 2008 · PubMed Central
  7. Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
    Filip Krag Knop, Katrine Bagge Hansen, Filip Krag Knop · 2010 · Diabetes Metabolic Syndrome and Obesity
  8. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs
    Rolf Mentlein · 2005 · Expert Opinion on Investigational Drugs
  9. The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers
    Neha Shrestha, Oriane Bouttefeux, Kévin Vanvarenberg, Patrik Lundquist, Juan Cuñarro, Sulay A. Tovar, Georgiy R. Khodus, Ellen Andersson, Åsa V. Keita, Carlos Gonzalez Dieguez et al. · 2017 · Nanoscale
  10. Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
    Scott R. Drab · 2010 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  11. Liraglutide in the management of type 2 diabetes
    Estela Wajcberg, Amatur Amarah · 2010 · Drug Design Development and Therapy
  12. Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
    Ana Dias Martins, Mariana Pereira Monteiro, Branca Maria Silva, Alberto Barros, Mário Sousa, Rui A. Carvalho, Pedro Fontes Oliveira, Marco Gouveia Alves · 2018 · Toxicology and Applied Pharmacology
  13. Incretin-based therapies: mimetics versus protease inhibitors
    Patricia Lee Brubaker · 2007 · Trends in Endocrinology and Metabolism
  14. Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
    Debbie Hinnen, Loretta L. Nielsen, A. Waninger, P. Kushner · 2006 · The Journal of the American Board of Family Medicine
  15. Liraglutide: clinical pharmacology and considerations for therapy
    Sisson, Evan M. · 2011 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
  16. Diabetes mellitus and gastric emptying: questions and issues in clinical practice
    Melvin Samsom, Adil E. Bharucha, John E. Gerich, Kathrin Herrmann, Jörg Limmer, Rainer Linke, David G. Maggs, Jörg R. J. Schirra, Adrian V Vella, Hans‐Jürgen Wörle et al. · 2009 · Diabetes/Metabolism Research and Reviews
  17. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists
    Cesare Berra, Roberto Manfrini, Damiano Regazzoli, Maria Grazia Radaelli, Olga Disoteo, Carmen Sommese, Paolo Fiorina, Giuseppe Ambrosio, Franco B. Folli · 2020 · Pharmacological Research
  18. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
    Kohei Kaku, Mads Frederik Rasmussen, Tomoyuki Nishida, Yutaka Seino · 2011 · Journal of Diabetes Investigation
  19. Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
    James B. Reilly, Jeffrey S. Berns · 2010 · Seminars in Dialysis
  20. Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
    Mikkel Christensen, Filip Krag Knop · 2010 · Current Diabetes Reports
  21. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
    Thomas H. Claus, Clark Q. Pan, Joanne M. Buxton, Ling Yang, Jennifer C Reynolds, Nicole Barucci, Michael G. Burns, Astrid A. Ortiz, Steve Roczniak, James N. Livingston et al. · 2007 · Journal of Endocrinology
  22. Novel Pharmacologic Agents for Type 2 Diabetes
    Gabriel Ikponmosa Uwaifo, Robert E. Ratner · 2005 · Endocrinology and Metabolism Clinics of North America
  23. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes
    Nauck, Michael A., Kahle, Melanie, Baranov, Oleg, Deacon, Carolyn F., Holst, Jens J. · 2017 · Diabetes, Obesity and Metabolism
  24. Review of the Therapeutic Uses of Liraglutide
    Gina J. Ryan, Karla T. Foster, Lynetta M. Johnson · 2011 · Clinical Therapeutics
  25. A Possible Role of GLP-1 in the Pathophysiology of Early Dumping Syndrome
    Yamamoto, Hiroshi, Mori, Tsuyoshi, Tsuchihashi, Hiroshi, Akabori, Hiroya, Naito, Hiroyuki, Tani, Tohru · 2005 · Digestive Diseases and Sciences
  26. Liraglutide
    Caroline M. Perry · 2011 · Drugs
  27. Degradation, Insulin Secretion, and Antihyperglycemic Actions of Two Palmitate-DerivitizedN-Terminal Pyroglutamyl Analogues of Glucose-Dependent Insulinotropic Polypeptide
    Nigel Irwin, Brian D. Green, Victor A. Gault, Brett Greer, Patrick Harriott, Clifford J. Bailey, Peter R. Flatt, Finbarr P.M. O'Harte · 2005 · Journal of Medicinal Chemistry
  28. Cardiovascular safety and benefits of GLP-1 receptor agonists
    Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll, Filip Krag Knop · 2017 · Expert Opinion on Drug Safety
  29. Lixisenatide, a novel GLP ‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
    Geremia B. Bolli, David R. Owens · 2013 · Diabetes Obesity and Metabolism
  30. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
    Kapitza, Christoph, Zdravkovic, Milan, Hindsberger, Charlotte, Flint, Anne · 2011 · Advances in Therapy
  31. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
    Gian Paolo Fadini, Mauro Rigato · 2014 · Diabetes Metabolic Syndrome and Obesity
  32. Preparation and characterization of a novel exendin‐4 human serum albumin fusion protein expressed in Pichia pastoris
    Yan‐Shan Huang, Zhi Chen, Yi‐Qiong Chen, Guo‐Chang MA, Jian‐Feng Shan, Wei Liu, Linfu Zhou · 2007 · Journal of Peptide Science
  33. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers
    Su Young Chae, Young Goo Chun, Seulki Lee, Cheng‐Hao Jin, Eun Seong Lee, Kang Choon Lee, Yu Seok Youn · 2008 · Journal of Pharmaceutical Sciences
  34. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes
    Fernando Gómez Peralta, Cristina Abreu, Jose Carlos Castro, Elvira Alcarria, Margarita Cruz-Bravo, Maria Jesús Garcia-Llorente, Cristina Albornos, Concepción Moreno, María Cepeda, Francisca Almodóvar · 2015 · BMC Endocrine Disorders
  35. Focus on therapeutic peptides and their delivery
    Elise Rosson, François Lux, Laurent David, Yann Godfrin, Olivier Tillement, Eloïse Thomas · 2025 · International Journal of Pharmaceutics
  36. Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
    David G. Maggs, Ian Andrew Macdonald, Michael Albrecht Nauck · 2007 · Diabetes Obesity and Metabolism
  37. Discovery of Tarantula Venom-Derived NaV1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis
    Bin Wu, Justin K. Murray, Kristin L. Andrews, Kelvin K. C. Sham, Jason Long, Jennifer Aral, Joseph Ligutti, Shanti M. Amagasu, Dong Liu, Anruo Zou et al. · 2018 · Journal of Medicinal Chemistry
  38. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
    Lei Qin, Stephanie Chen, Emuella M. Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez, Susan Grandy · 2017 · Diabetes Therapy
  39. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
    Åke Sjöholm · 2010 · Pharmaceuticals
  40. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes
    Michael J Riedel, Daniel F. Gaddy, Ali Asadi, Paul D. Robbins, Timothy J. Kieffer · 2009 · Gene Therapy
  41. A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life
    Joel Lindgren, Essam Refai, Sergei V Zaitsev, Lars Abrahmsén, Per‐Olof Berggren, Amelie Eriksson Karlström · 2014 · Biopolymers
  42. Glucagon-like peptide 1 (GLP-1) and metabolic diseases
    Carlo Maria Rotella, Laura Pala, Edoardo Mannucci · 2005 · Journal of Endocrinological Investigation
  43. GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
    Heinla, Keiu, Vasar, Eero, Reppo, Ingrid, Sedman, Tuuli, Volke, Vallo · 2023 · Diabetes Therapy
  44. Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long‐Acting, Potent Glucagon‐Like Peptide‐1 Analog
    Jerry D. Meece · 2009 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  45. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
    Claudio Daniel González, Valeria Beruto, Guillermo Alberto Keller, Silvina Santoro, Guillermo Di Girolamo · 2006 · Expert Opinion on Investigational Drugs
  46. Pharmacotherapy of Diabetes: New Developments
    Carl Erik Mogensen · 2007 · Springer eBooks
  47. Strategies to Optimize Peptide Stability and Prolong Half-Life
    Sophia M. Shi, Li Di · 2022 · AAPS advances in the pharmaceutical sciences series
  48. Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
    R. Keith Campbell, Joshua J. Neumiller · 2010 · Diabetes Metabolic Syndrome and Obesity
  49. Gut peptides in the treatment of diabetes mellitus
    Torsten Peter Vahl, David A. D’Alessio · 2004 · Expert Opinion on Investigational Drugs
  50. The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects
    Ji Jiang, Jianyan Zhang, Lisbeth Vestergård Jacobsen, Pei Hu · 2011 · The Journal of Clinical Pharmacology
  51. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
    Jens Juul Holst, John B. Buse, Helena W. Rodbard, Sultan Linjawi, Vincent C. Woo, Trine Welløv Boesgaard, Kajsa Kvist, Stephen C. L. Gough · 2015 · Journal of Diabetes Science and Technology
  52. Unravelling Polycystic Ovary Syndrome and Its Comorbidities
    Kyung-Wook Kim · 2021 · Journal of Obesity & Metabolic Syndrome
  53. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed‐ratio combination therapy
    Christoph Kapitza, Bruce W. Bode, Steen H. Ingwersen, Lisbeth Vestergård Jacobsen, Pernille Poulsen · 2015 · The Journal of Clinical Pharmacology
  54. Novel therapeutic agents for the treatment of diabetic kidney disease
    Rachel E. Hartman, Shantanu Rao, Mariann D. Churchwell, Susan J. Lewis · 2020 · Expert Opinion on Investigational Drugs
  55. Vascular Complications of Diabetes Mellitus
    Yien Chiong, Carmella Evans‐Molina · 2014 · Springer eBooks
  56. Cardiovascular Effects of Incretin-Based Therapies
    William B. White, William L. Baker · 2016 · Annual Review of Medicine
  57. The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
    Jianqiu Gu, Meng Xin, Yan Ping Guo, Lei Wang, Hongzhi Zheng, Yixuan Liu, Bingshu Wu, Difei Wang · 2016 · Scientific Reports
  58. Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
    Revathi Sekar, Kailash Singh, Aloysius Wilfred Raj Arokiaraj, Bkc Chow · 2016 · International review of cytology
  59. Liraglutide in the treatment of obesity
    Sarah Yoon Ai Ng, John P.H. Wilding · 2014 · Expert Opinion on Biological Therapy
  60. Differential mobility spectrometry tandem mass spectrometry with multiple ion monitoring for the bioanalysis of liraglutide
    Xiangjun Meng, Haitong Xu, Zhi Zhang, J. Paul Fawcett, Junru Li, Yan Yang, Jingkai Gu · 2017 · Analytical and Bioanalytical Chemistry
  61. Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations
    George S. Jeha, Rubina A. Heptulla · 2006 · Pediatric Diabetes
  62. Octreotide improves early dumping syndrome potentially through incretins: a case report
    Daisuke Sato, Katsutaro Morino, Natsuko Ohashi, Emi Ueda, Kazuhiro Ikeda, Hideka Yamamoto, Satoshi Ugi, Hiroshi Yamamoto, Shin‐ichi Araki, Hiroshi Maegawa · 2013 · Endocrine Journal
  63. The GLP‐1 system as a therapeutic target
    Mark C. B. Edwards · 2005 · Annals of Medicine
  64. Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
    Daisuke Yabe, Yutaka Seino · 2011 · Clinical Medicine Insights Endocrinology and Diabetes
  65. Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
    Cláudia Matta-Coelho, Laurence J. Dobbie, James Crane, Abdel Douiri, Annastazia Learoyd, Olanike Okolo, Spyros Panagiotopoulos, Dimitri J. Pournaras, Sasindran Ramar, Francesco Rubino et al. · 2023 · International Journal of Obesity
  66. An Ultrasensitive UPLC–MS/MS Assay for the Quantification of the Therapeutic Peptide Liraglutide in Plasma to Assess the Oral and Nasal Bioavailability in Beagle Dogs
    Max Sauter, Philipp Uhl, Marius Majewsky, Margaux Fresnais, Walter E. Haefeli, Jürgen Burhenne · 2019 · Bioanalysis
  67. Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics
    Riccardo Perfetti · 2011 · Diabetes Technology & Therapeutics
  68. Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists
    Sun, Lei, Zheng, Zhi-Ming, Shao, Chang-Sheng, Zhang, Zhi-Yong, Li, Ming-Wei, Wang, Li, Wang, Han, Zhao, Gen-Hai, Wang, Peng · 2022 · Pharmaceuticals
  69. Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs
    Hongbing Lin, Jinbin Liu, Yulin Hou, Zhiyan Yu, Juan Hong, Jianghong Yu, Yu Chen, Jingwen Hu, Dengning Xia · 2024 · Drug Delivery and Translational Research
  70. Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide
    Christoph Kapitza, Milan Zdravkovic, Eric Zijlstra, Stine Segel, Tim Heise, Anne Flint · 2010 · The Journal of Clinical Pharmacology
  71. Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes
    Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella, Ferdinando Carlo Sasso · 2007 · Current Diabetes Reviews
  72. Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices
    Udo Stauder, Diplom Enginee, Hina Elton, Alfred Penfornis, Steven V. Edelman · 2014 · Journal of Diabetes Science and Technology
  73. Opportunities of Antidiabetic Drugs in Cardiovascular Medicine
    Cen Yan, Lutgarde Thijs, Yu Cao, Sander Trenson, Zhen‐Yu Zhang, Stefan P. Janssens, Jan Albert Staessen, Yingmei Feng · 2020 · Hypertension
  74. Obesity‐related genes are expressed in human Sertoli cells and modulated by energy homeostasis regulating hormones
    Sara Pereira, Ana Dias Martins, Bruno P. Moreira, Raquel L. Bernardino, Alberto Barros, Mariana Pereira Monteiro, Pedro Fontes Oliveira, Marco Gouveia Alves · 2020 · Journal of Cellular Physiology
  75. Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir
    Karen‐Margrethe Pedersen, Anna Katrina Jógvansdóttir Gradel, Trine Pagh Ludvigsen, Berit Østergaard Christoffersen, Caroline Amalie Fuglsang-Damgaard, Kristian Moss Bendtsen, Suzi Høgh Madsen, Valentina Manfé, Hanne H. F. Refsgaard · 2021 · Translational research
  76. The incretin system and cardiometabolic disease
    Paul E. Szmitko, Lawrence A. Leiter, Subodh Verma · 2010 · Canadian Journal of Cardiology
  77. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
    Ajay Kumar · 2014 · Expert Opinion on Biological Therapy
  78. MFPPDB: a comprehensive multi-functional plant peptide database
    Yaozu Yang, Hongwei Wu, Yu Gao, Wei Tong, Ke Li · 2023 · Frontiers in Plant Science
  79. Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry
    Fateme Chavoshy, Seyedeh Zohreh Mirjalili, Ali Mohammadi, Mohsen Amini, Govert W. Somsen, Mehrnoosh Shirangi · 2024 · International Journal of Peptide Research and Therapeutics
  80. Individualised incretin-based treatment for type 2 diabetes
    Michael Albrecht Nauck, Juris Jendrik Meier · 2010 · The Lancet
  81. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea
    S H Ingwersen, Kristin C. Carlsson Petri, Nikhil Tandon, K-H Yoon, L. Chen, Jiten P Vora, Wenying Yang · 2015 · Diabetes Research and Clinical Practice
  82. Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management
    Alan J. Garber · 2005 · Diabetes Obesity and Metabolism
  83. Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
    Lyn H. Jones, David A. Price · 2013 · Progress in medicinal chemistry
  84. The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management
    Octaviano A Roges, Marilyn Baron, Athena Philis‐Tsimikas · 2005 · Expert Opinion on Investigational Drugs
  85. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
    Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, Meong Cheol Shin · 2023 · Pharmaceutics
  86. Liraglutide protects pancreatic beta cells during an early intervention in G ato‐ K akizaki rats (Gato‐Kakizaki大鼠使用利拉鲁肽进行早期干预可以保护胰腺β细胞)
    Xiu Luo, Linlin Pan, Aifang Nie, Qidi Wang, Yanyun Gu, Fengying Li, Hongli Zhang, Wenyi Li, Xiaoying Li · 2013 · Journal of Diabetes
  87. Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct
    Feng Qian, Nina Ni, Lori Burton, Yue Fen Wang, Sridhar Desikan, Munir A. Hussain, Ronald L. Smith · 2009 · International Journal of Pharmaceutics
  88. A comparison of the cellular and biological properties of DPP‐IV‐resistant N‐glucitol analogues of glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide
    BD Green, Victor A. Gault, Finbarr P.M. O'Harte, Peter R. Flatt · 2004 · Diabetes Obesity and Metabolism
  89. Pharmacotherapy of hyperglycemia
    Kristen M. Kulasa, Robert R. Henry · 2009 · Expert Opinion on Pharmacotherapy
  90. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
    Julia Katharina Mader, Lene Jensen, Steen H. Ingwersen, Erik Christiansen, Simon R. Heller, Thomas Rudolf Pieber · 2016 · Clinical Pharmacokinetics
  91. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
    Gina J. Ryan, Yolanda M. Hardy · 2010 · Journal of Clinical Pharmacy and Therapeutics
  92. Treatment of diabetes with glucagon-like peptide-1 gene therapy
    Michael J Riedel, Timothy J. Kieffer · 2010 · Expert Opinion on Biological Therapy
  93. Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
    Domenico Tricò, Anna Solini · 2021 · Advances in Chronic Kidney Disease
  94. Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
    Sam Lear, Zaid Amso, Weijun Shen · 2019 · Methods in enzymology on CD-ROM/Methods in enzymology
  95. Glucagon‐like peptide‐1‐based therapies: new developments and emerging data
    Alan J. Garber · 2008 · Diabetes Obesity and Metabolism
  96. Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
    David Joffe · 2010 · American Journal of Health-System Pharmacy
  97. A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic
    Samaneh Ahmadi, Mohammad Bagher Shahsavani, Zohreh Tavaf, Rawayh Muslim Albaghlany, Ashutosh Kumar, Ali Akbar Moosavi‐Movahedi, Reza Yousefi · 2022 · PLoS ONE
  98. Building a BioChemformatics Database
    Jan Holst Jensen, Thomas Høeg-Jensen, Søren Berg Padkjær · 2008 · Journal of Chemical Information and Modeling
  99. Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
    Carolyn Robertson · 2011 · Diabetes Spectrum
  100. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes
    Kira Harris, Kimberly Lovin Nealy · 2017 · Annals of Pharmacotherapy